2019
Knowledge of, and beliefs about, access to screening facilities and cervical cancer screening behaviors among low-income women in New Jersey
Silvera SAN, Bandera EV, Jones BA, Kaplan AM, Demisse K. Knowledge of, and beliefs about, access to screening facilities and cervical cancer screening behaviors among low-income women in New Jersey. Cancer Causes & Control 2019, 31: 43-49. PMID: 31720918, PMCID: PMC9083372, DOI: 10.1007/s10552-019-01244-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCross-Sectional StudiesEarly Detection of CancerEthnicityFemaleHealth Knowledge, Attitudes, PracticeHealth Services AccessibilityHealth Status DisparitiesHealthcare DisparitiesHumansLogistic ModelsMass ScreeningMiddle AgedMultivariate AnalysisNew JerseyPapanicolaou TestPovertyRacial GroupsRiskUterine Cervical NeoplasmsVaginal SmearsYoung AdultConceptsLow-income womenCervical cancerCancer outcomesCervical cancer outcomesMultivariate logistic regressionCross-sectional studyPap testingPap testCancer screeningInsurance statusCancer testsPrevention strategiesEthnic disparitiesLogistic regressionSocioeconomic differencesCancerWomenAffordable screeningScreening facilityScreeningOutcomesRisk awarenessNew JerseyYears
2005
Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival
Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H. Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecologic Oncology 2005, 100: 330-337. PMID: 16199080, DOI: 10.1016/j.ygyno.2005.08.035.Peer-Reviewed Original ResearchConceptsOvarian cancer treatmentDisease progressionGSTP1 genotypesGST polymorphismsPrimary epithelial ovarian cancerCox proportional hazards regressionFunctional polymorphismsGSTP1 Ile/IleCancer treatmentGSTP1 Ile/ValGlutathione S-transferase polymorphismsGSTM1 null patientsPost-operative chemotherapySubgroup of patientsProportional hazards regressionEpithelial ovarian cancerOvarian cancer survivalEffect of chemotherapyOvarian cancer prognosisOvarian cancer progressionVal/ValIle/IleIle/ValOverall survivalTumor characteristics
1997
Time trend of female breast carcinoma In Situ by race and histology in Connecticut, U.S.A.
Zheng T, Holford T, Chen Y, Jones B, Flannery J, Boyle P. Time trend of female breast carcinoma In Situ by race and histology in Connecticut, U.S.A. European Journal Of Cancer 1997, 33: 96-100. PMID: 9071907, DOI: 10.1016/s0959-8049(96)00371-1.Peer-Reviewed Original ResearchConceptsAge-adjusted incidence ratesSitu breast cancerFemale breast carcinomaIncidence rateBreast cancerMammography screeningBreast carcinomaOverall age-adjusted incidence rateAge group 40 yearsAge groupsEarly-stage breast cancerAge-specific incidence ratesFemale breast cancer incidenceConnecticut Tumor RegistryBreast cancer incidenceStage breast cancerEfficacy of mammographyFemale breast cancerAge group 40Older age groupsTime trendsTumor RegistryIncident casesDuctal carcinomaCancer incidence
1995
Can mammography screening explain the race difference in stage at diagnosis of breast cancer?
Jones B, Kasl S, Curnen M, Owens P, Dubrow R. Can mammography screening explain the race difference in stage at diagnosis of breast cancer? Cancer 1995, 75: 2103-2113. PMID: 7697601, DOI: 10.1002/1097-0142(19950415)75:8<2103::aid-cncr2820750813>3.0.co;2-2.Peer-Reviewed Original ResearchConceptsBreast cancerWhite womenMammography screeningLate-stage diagnosisPopulation-based dataDevelopment of symptomsLate-stage cancerBlack womenAfrican American womenRace differencesRace-specific analysesScreening historyObserved race differencesRetrospective studyMammographic screeningActive surveillanceConnecticut hospitalsStage cancerCancerDiagnosisSocioeconomic statusWomenStage diagnosisSignificant predictorsAmerican women